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following questionnaires: the EPIC-50, the International Prostate 
Symptom Score (IPSS), the Sexual Health Inventory for men 
(SHIM), and the EORTC QLQ PR25. Analyses were conducted using 
the SAS 9.3 software (2012, SAS Institute, Cary, NC, USA) and the 
alpha level was set at 5%. 
Results: The internal consistency of the EPIC was demonstrated 
by significant item-total correlations and elevated Cronbach’s 
alpha for each subscale (urinary: r = .25-.80; α = .85; intestinal: 
r = .27 - .73; α = .84; sexual: r = .48 - .80; α = .92; hormonal: r = 
.21-.71; α = .80). Strong and significant correlations were found 
between EPIC-urinary subscale and IPSS total score (r =- .71, p < 
.01) and between EPIC-sexual subscale and SHIM total score (r = 
.79, p < .01), thus supporting the convergent validity of the EPIC. 
The test-retest reliability was excellent with strong and 
significant correlations obtained between the two 
administrations (urinary: r = .90; intestinal: r = .84; sexual: r = 
.88; hormonal:  r = .79) and the absence of significant differences 
between T1 and T2 mean scores. Finally, a significant 
deterioration was found on all EPIC subscales from pre- to post-
treatment thus indicating that the tool is sensitive to clinical 
change. 
Conclusions: Our French Canadian version of the EPIC-50 appears 
to provide a reliable and valid assessment of quality of life in 
prostate cancer patients. Future analyses will investigate its 
factorial structure and the psychometric properties of the 
abbreviated version. 
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THE INFLUENCE OF DOSIMETRY ON ACUTE URINARY TOXICITY IN 
HDR PROSTATE BRACHYTHERAPY  
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Mondat, Djamal Berbiche, Marjorie Jolicoeur 
University of Sherbrooke, Greenfield Park, QC  
 
Purpose: Although high-dose rate (HDR) brachytherapy boost is 
widely used in intermediate and high-risk prostate cancer 
treatment, the appropriate dose constraints are still evolving. 
The aim or our study is to analyze the influence of patient 
characteristics as well dosimetric parameter specifically the 
V150 (volume receiving 150% of the dose), on acute urinary 
toxicities.  
Methods and Materials: We retrospectively analyzed 231 
consecutive patients treated, between May 2012 and September 
2014, with HDR brachytherapy boost in our institution. The 
CTCAE V3 criteria were used to grade the urinary symptoms. 
However, we wanted to separately analyze patients with urinary 
obstruction requiring urinary catheter for longer than 24 hours. 
For the purpose of our analysis, we used a value of 35% as a cut 
off for the V150. Other dosimetric parameters were also 
analyzed. Pearson’s correlations as well as logistic regressions 
were performed. 
Results: During a median follow up of 18.6 months, 29% of 
patients had no urinary toxicity, 28% had Grade 1 and 38% had 
Grade 2 or 3 urinary toxicities. Eleven patients (5%) needed a 
urinary catheter for longer than 24 hours because of urinary 
obstruction. Although not significant (p = 0.0951), we found an 
important difference between the mean prostate volume of 
patients needing urinary catheter (51 cc) versus those who did 
not (42 cc). Among different patient characteristics such as 
tobacco use, dyslipidemia, hypertension, coronary heart disease 
and hormone therapy treatments, only the use of hormone 
therapy at the time of HDR treatment significantly increased 
urinary toxicity (p = 0.0462). A V150 ≥ 35% did not significantly 
influence Grade 1 (p = 0.2204) or Grade 2-3 (p = 0.8162) urinary 
toxicity, nor did it significantly influence the need for urinary 
catheter placement (p = 0.1678). However, in the 11 patients for 
whom a urinary catheter was needed, the median V150 and Dmax 
to the urethra (maximal dose to the urethra) were 42% and 
124.78% respectively. 
Conclusions: In conclusion, the only significant prognostic factor 
for urinary retention requiring prolonged catheter placement 
was the use of hormone therapy. We did not find a significant 
influence of dosimetric parameters, specifically the V150, on 
acute urinary toxicity. However, due to the small sample size of 
patients requiring a urinary catheter we cannot conclude on the 
influence of the V150 for those patients. Nevertheless, we 
strongly believe that the V150 should be kept as low as possible 
since in our cohort the median V150 for the patients requiring a 
urinary catheter for obstructive symptoms was 42%. 
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EVALUATION OF MILK OF MAGNESIA TO REDUCE VARIATION IN 
RECTAL FILLING IN IMAGE GUIDED VOLUMETRIC MODULATED 
ARCH THERAPY OF PROSTATE CANCER 
Ali Hosni, Tara Rosewall, Timothy Craig, Vickie Kong, Andrew 
Bayley, Charles Catton, Peter Chung 
Princess Margaret Cancer Centre, University of Toronto, Toronto, 
ON 
 
Purpose: To investigate the effect of milk of magnesia (MoM) on 
consistency of interfraction rectal filling and acute rectal 
toxicity. 
Methods and Materials: Two groups were retrospectively 
identified, each consisting of 40 patients with localized prostate 
cancer treated with VMAT to prostate +/- seminal vesicles, to 
prescribed dose of 78 Gy in 39 fractions over eight weeks. The 
first group were instructed to follow a bowel regimen with 
antiflatulent diet and MoM started three days prior to planning 
CT scan (P-CT) and continued during RT, while the second group 
followed simple dietary advice to achieve an empty rectum. The 
rectum between the upper and lower borders of the clinical 
target volume (CTV) was delineated by a single observer on the 
P-CT and on eight, weekly cone beam CT (CBCT). Rectal filling 
was assessed by measurement of anterio-posterior diameter of 
the rectum at the superior and mid levels of CTV, and by 
calculation of rectal volume (RV) and the average cross-sectional 
rectal area (CSA; defined as the rectal volume divided by length). 
The differences in these measurements were compared between 
the two groups by repeated measures analysis. Data relating to 
acute toxicity was extracted from patients’ medical charts. 
Results: A total of 720 images, including 80 P-CT and 640 CBCT 
images from 80 patients were analyzed. All images showed 
satisfactory visualisation of the rectum at the level of CTV. Using 
linear mixed models, and after adjusting for baseline values at 
the time of P-CT to test the differences in rectal dimensions 
between both groups over the eight-week treatment period, 
there were no significant differences either in rectal volume (p 
= 0.58), average CSA (p = 0.63), anterio-posterior diameter of 
rectum at superior level of CTV (p = 0.95) or at mid level of CTV 
(p = 0.28). In the MoM group, the mean volume of MoM taken by 
patients was 31 cm3 (range, 15–45 cm3) in the first week and 13 
cm3 (range, 0–30 cm3) in the last week. The proportion of 
patients who took MoM decreased from 100% in the first week to 
60% in the last week. Acute RTOG rectal toxicity in MoM/non-
MoM groups consisted of G2 diarrhea (n = 3/2), G1 diarrhea (n = 
21/7), G1 proctitis (n = 5/5). 
Conclusions: MoM did not appear to reduce the interfraction 
variation in rectal filling compared to simple dietary advice. MoM 
may cause diarrhea and a substantial proportion of patients 
discontinued its use by the end of radiation treatment. 
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LONG-TERM OUTCOMES OF STAGE II SEMINOMAS  
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Purpose: To review the long-term outcomes for patients with 
Stage II Seminoma treated at our institute. 
Methods and Materials: We included all patients referred and 
registered with Stage I or II Seminoma in our Cancer Registry, 
from 1984. Patients with unknown stage or histology were 
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excluded. The query identified 142 patients who received 
treatment for clinical Stage II disease. Median age was 38 years 
(range: 19 – 68), 33 had Stage IIA, 47 IIB, and 62 had IIC disease. 
Fifty-nine patients were treated with radiation therapy (RT) 
while 83 received chemotherapy (CT). Only three patients with 
Stage IIA got CT, and only five with IIC got RT. Median RT dose 
was 30 Gy. Most common CT regimens used were EP (n = 68) and 
BEP (n = 13). 
Results: After a median follow up of 18 years, 24 patients had 
died, and there were 16 recurrences (three in the contra-lateral 
testis). Patients were more likely to die of second cancers (n = 
7) and myocardial infarctions (n = 6), than from progressive 
Seminoma (n = 3). Two patients died during treatment 
(neutropenia and sepsis). The 10- and 15-year overall survival 
(OS) was, IIA: 93.8% and 93.8%; IIB: 91.4% and 88.3%; IIC: 83.2% 
and 76.0%. The 10-year cumulative incidence of relapse (CIR) for 
Stage IIA patients treated with RT was 3.4%. Stage IIC patients 
treated with CT had a 10-yr CIR of 10.6%. The 10-year CIR for 
Stage IIB patients treated with RT (n = 24) versus CT (n = 23) was 
29.8% versus 0% (p = 0.005). Seventeen patients developed a 
second malignancy (SM); non-melanoma skin cancers were 
excluded. The 15-year cumulative incidence of SM was 7.3% for 
patients treated with RT, versus 9.7% for those treated with CT 
(p = 0.321). 
Conclusions:  Long-term outcomes for patients with Stage II 
Seminoma continue to be excellent. Patients are more likely to 
die of second cancers and cardiovascular disease than from 
progressive seminoma. 
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Purpose: To describe the practice of adjuvant brachytherapy 
(BT) and external beam radiotherapy (EBRT) for management of 
endometrial cancer.  
Methods and Materials: An electronic survey including 83 
questions focusing on general/demographic information, pre-
treatment assessments, radiotherapy policies and EBRT/BT 
techniques was sent to all 14 regional cancer centres in 2014.  
Results: The response rate was 100%. The most frequently used 
dose/fractionation scheme for EBRT was 45 Gy in 25 fractions. 
The EBRT technique was 4-Field box in 46%, IMRT in 15%, VMAT 
in 31% and VMAT/4-Field box in 8% of the centres. Pelvic EBRT 
was recommended by all centres for Stage II/IIIA/IIIC1 any grade, 
by 92% of the centres with Stage IB Grade 3 or serous-clear cell 
carcinoma/Stage IIIC2 any grade and by 70% of the centres for 
Stage IA serous-clear cell carcinoma. Combination of EBRT and 
BT was recommended by all centres for Stage II any grade 
carcinoma, by 92% of the centres for Stage IIIC1 with cervical 
stromal involvement, by 85% of the centres for Stage 
IIIA/IIIB/IIIC2 with cervical stromal involvement and by 54% of 
the centres for Stage IVB any grade with cervical stromal 
involvement. Adjuvant BT alone was recommended for Stage 1A 
Grade 3 or Stage 1B Grade 1-2 in 77% of the centres, for Stage 
1A serous-clear cell carcinoma in 31% of centres, for Stage 1B 
Grade 3 in 15% of centres. In 85% of centres, the cases were 
always peer reviewed. Half of the centres used image 
verification with x-ray/CT/fluoroscopy after each insertion of 
the applicator. Bladder and rectal doses were recorded in 8% of 
the centres using ICRU 38 point doses and in 25% using dose-
volume metrics (D2cc). Seventeen percent of the centres treated 
the upper 3 cm of the vagina, 42% the upper 4 cm, 8% the upper 
3-4 cm, 8% the upper 5 cm, 17% the upper half and 8% the upper 
third of the vagina. The dose was prescribed at the surface of 
the cylinder and at a depth of 5 mm in 33% and 67% of the 
centres, respectively. The dose for BT alone prescribed to the 
surface varied from 6-10.5 Gy x 3-5 fractions. The dose was more 
uniform when prescribed at depth, with 87% using 7 Gy x 3 
fractions. For combination EBRT-BT treatments, BT dose varied 
from 5-6 Gy x 3 fractions at the surface to 4-5.5 Gy x 2-3 fractions 
at depth.  
Conclusions: Practice patterns regarding the use of EBRT and BT 
appear to be fairly consistent across the province of Ontario, 
however, there is considerable heterogeneity in BT treatment 
planning practices, particularly with respect to length of vagina 
treated, prescription points, and dose/fractionation. Further 
research is required to determine the reasons for this 
heterogeneity, to identify areas where harmonization of practice 
might lead to clinically significant benefits, and to generate 
evidence–based practice recommendations for the use of EBRT 
and BT in the province of Ontario. 
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Purpose: Our region has higher than provincial average smoking 
rates and alcohol consumption and lower human papillomavirus 
(HPV) vaccination rates. These have contributed to high 
incidence and poor prognosis of head and neck squamous cell 
carcinoma (HNSCC) in the past. This study reviews our single 
institution experience with Stage 4A and 4B HNSCC outcomes 
during 4 years since we adopted Intensity Modulated 
Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT) 
and Image-guided Radiation Therapy (IGRT). 
Methods and Materials: All charts of patients with head and neck 
malignancy between August 2009 and July 2013 were reviewed. 
Total of 195 consecutive patients met the selection criteria for 
analysis. There were 100 Stage 4A or 4B locally advanced HNSCC 
(AJCC-7). 
Results: Median age was 63 years (36-88), 81% were male, 21% 
were P16 positive (the most biologically relevant indicator for 
HPV-induced oropharyngeal squamous cell carcinoma), 74% had 
two or more major comorbidities. Most common sites are 
oropharynx (52%), hypopharynx (13%) and larynx (10%). Majority 
96% received radiotherapy, including 90% IMRT and 37% VMAT, 
86% received 50 Gy or higher dose, 39% had surgery, and 62% had 
chemotherapy. Using Kaplan-Meier life table, the 2/3 year local 
regional control rates are 82.8% and 80.5% respectively, and the 
2/3 year overall survival rates are 62.3% and 57.4% respectively. 
Median survival has not been reached. There was no treatment 
related death and 25% had Grade 3-4 acute toxicity (RTOG Acute 
Radiation Morbidity Scoring Criteria). 
Conclusions: Stage 4A and 4B HNSCC outcome in our institution 
is better than historical data. This might be due to our 
multidisciplinary approach and the introduction of new 
technology including IMRT, VMAT, and IGRT. Normal tissue 
tolerance dose constraints usually can be met using IMRT or 
VMAT. The local regional control and overall survival is excellent 
despite significant comorbidities associated with unhealthy life 
style in this region. 
 
 
 
 
 
